<p>Vanda Pharmaceuticals (VNDA) 修订了其 2025 年全年收入指引，将预期的上限从 2.5 亿美元下调至 2.3 亿美元，恰逢其即将发布的第三季度财报。</p>
<p>查看我们对 Vanda Pharmaceuticals 的最新分析。</p>
<p>投资者注意到 Vanda Pharmaceuticals 下调的收入展望，尤其是在第三季度业绩即将公布之际。过去一周，股价急剧下滑 20.91%，反映出在指引下调后情绪的变化。同时，过去 90 天上涨 3.82% 暗示市场在重新评估未来前景时的波动性。1 年总股东回报为-6.65%，多年来表现不佳，动能依然疲软，市场上弥漫着谨慎的气氛。</p>
<p>如果近期制药行业的波动让你在寻找机会，现在是查看完整的医疗股票列表的好时机。</p>
<p>随着股价接近 52 周低点，预期也已重置，投资者可能会想知道 Vanda Pharmaceuticals 是否在其财报发布前是一个被低估的机会，或者市场是否准确反映了公司的增长前景。</p>
<h2>最受欢迎的叙述：65.7% 被低估</h2>
<p>Vanda Pharmaceuticals 最受关注的估值叙述将其公允价值远高于最后的收盘价，暗示如果假设的增长轨迹实现，将有巨大的上行空间。考虑到价格目标中包含如此多的潜力，让我们看看一个关键驱动因素，可能会改变当前的故事。</p>
<blockquote>
<p>最近的商业发布和针对双相 I 型障碍的 Fanapt 及针对多发性硬化症的 PONVORY 的销售团队持续扩张，已经推动了处方和收入的增长，并且有望捕捉全球对精神病和神经治疗日益增长的需求，支持持续的收入增长。</p>
</blockquote>
<p>阅读完整的叙述。</p>
<p>想知道是什么推动了这个大胆的公允价值吗？该叙述的计算依赖于对收入和利润率的雄心勃勃的增长轨迹，这超过了大多数同行。想知道哪些重磅管道假设和行业趋势证明了这些高估值的未来倍数吗？看看是什么支撑了这个目标，以及分析师为何认为仍有如此多的上升空间。</p>
<p><strong>结果：公允价值为 12.67 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，传统药物的竞争加剧和成本上升可能会 derail 预期的增长。这使得 Vanda Pharmaceuticals 的任何转机都远非保证。</p>
<p>了解 Vanda Pharmaceuticals 叙述的关键风险。</p>
<h2>自建 Vanda Pharmaceuticals 叙述</h2>
<p>如果你对 Vanda Pharmaceuticals 有不同的看法或想得出自己的结论，可以在几分钟内探索基本面并分享你的观点，所以请随意按照自己的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对 Vanda Pharmaceuticals 的 2 个关键回报的乐观情绪。</p>
<h2>寻找更多投资想法？</h2>
<p>通过挖掘独特的主题和其他人可能忽视的增长潜力，提升你的投资组合。查看这些精心挑选的机会，并在大众发现之前确保你的下一个优势：</p>
<ul>
<li>通过评估这些 22 只股息收益率超过 3% 的高收益投资，解锁明天的潜力。</li>
<li>通过评估这 26 只强劲势头和行业领导地位的 AI 便士股票，发现人工智能的强大变化。</li>
<li>通过审查这些 81 只正在改变区块链和数字支付的加密货币和区块链股票，乘风破浪于去中心化金融的创新。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

Vanda制药

<p>Vanda 制药（VNDA）在发布第三季度财报前，将其 2025 年收入指引从 2.5 亿美元下调至 2.3 亿美元，导致过去一周股价下跌 20.91%。尽管在过去 90 天内股价上涨了 3.82%，但该公司的年度总股东回报率为-6.65%。分析师认为 VNDA 被低估，合理价值为 12.67 美元，主要受其精神病学和神经学治疗增长的推动。然而，竞争和成本上升对其增长轨迹构成风险</p>

<p>Vanda Pharmaceuticals (VNDA) revised its full-year 2025 revenue guidance, lowering the upper end of expectations to $230 million from $250 million just ahead of its upcoming third-quarter earnings release.</p>
<div class="lb-trans"><p>Vanda Pharmaceuticals (VNDA) 修订了其 2025 年全年收入指引，将预期的上限从 2.5 亿美元下调至 2.3 亿美元，恰逢其即将发布的第三季度财报。</p>
</div><p>See our latest analysis for Vanda Pharmaceuticals.</p>
<div class="lb-trans"><p>查看我们对 Vanda Pharmaceuticals 的最新分析。</p>
</div><p>Investors have taken note of Vanda Pharmaceuticals’ trimmed revenue outlook, especially with third-quarter results around the corner. The share price saw a sharp 20.91% slide over the last week, reflecting shifting sentiment after the guidance cut. Meanwhile, a 3.82% gain over the last 90 days hints at volatility as the market reassesses future prospects. With a 1-year total shareholder return of -6.65% and a multi-year trend of underperformance, momentum remains muted and caution is in the air.</p>
<div class="lb-trans"><p>投资者注意到 Vanda Pharmaceuticals 下调的收入展望，尤其是在第三季度业绩即将公布之际。过去一周，股价急剧下滑 20.91%，反映出在指引下调后情绪的变化。同时，过去 90 天上涨 3.82% 暗示市场在重新评估未来前景时的波动性。1 年总股东回报为-6.65%，多年来表现不佳，动能依然疲软，市场上弥漫着谨慎的气氛。</p>
</div><p>If recent pharma volatility has you scanning the sector for opportunities, it’s a great time to see the full list of healthcare stocks with See the full list for free.</p>
<div class="lb-trans"><p>如果近期制药行业的波动让你在寻找机会，现在是查看完整的医疗股票列表的好时机。</p>
</div><p>With shares sitting close to a 52-week low and expectations now reset, investors may wonder whether Vanda Pharmaceuticals is an undervalued opportunity ahead of its earnings or if the market is accurately reflecting the company’s growth prospects.</p>
<div class="lb-trans"><p>随着股价接近 52 周低点，预期也已重置，投资者可能会想知道 Vanda Pharmaceuticals 是否在其财报发布前是一个被低估的机会，或者市场是否准确反映了公司的增长前景。</p>
</div><h2>Most Popular Narrative: 65.7% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：65.7% 被低估</h2>
</div><p>Vanda Pharmaceuticals’ most-followed valuation narrative places its fair value far above the last closing price, suggesting major upside if the assumed growth trajectory is realized. With so much potential factored into the price target, let’s look at a key driver that could change the current story.</p>
<div class="lb-trans"><p>Vanda Pharmaceuticals 最受关注的估值叙述将其公允价值远高于最后的收盘价，暗示如果假设的增长轨迹实现，将有巨大的上行空间。考虑到价格目标中包含如此多的潜力，让我们看看一个关键驱动因素，可能会改变当前的故事。</p>
</div><blockquote>
<p>Recent commercial launches and ongoing expansion of the sales force for Fanapt in bipolar I disorder and PONVORY in multiple sclerosis have already driven prescription and revenue growth, and are positioned to capture increasing demand for psychiatric and neurological treatments globally, supporting sustained top-line growth.</p>
</blockquote>
<div class="lb-trans"><blockquote>
<p>最近的商业发布和针对双相 I 型障碍的 Fanapt 及针对多发性硬化症的 PONVORY 的销售团队持续扩张，已经推动了处方和收入的增长，并且有望捕捉全球对精神病和神经治疗日益增长的需求，支持持续的收入增长。</p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整的叙述。</p>
</div><p>Want to know what fuels this bold fair value? The narrative’s calculations rely on ambitious growth trajectories for both revenue and profit margins, which exceed most peers. Interested in which blockbuster pipeline assumptions and industry trends justify these elevated future multiples? See exactly what underpins this target and why analysts believe there is so much headroom still to capture.</p>
<div class="lb-trans"><p>想知道是什么推动了这个大胆的公允价值吗？该叙述的计算依赖于对收入和利润率的雄心勃勃的增长轨迹，这超过了大多数同行。想知道哪些重磅管道假设和行业趋势证明了这些高估值的未来倍数吗？看看是什么支撑了这个目标，以及分析师为何认为仍有如此多的上升空间。</p>
</div><p><strong>Result: Fair Value of $12.67 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 12.67 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, mounting competition for legacy drugs and rising expenses could derail expected growth. This makes any turnaround far from guaranteed for Vanda Pharmaceuticals.</p>
<div class="lb-trans"><p>然而，传统药物的竞争加剧和成本上升可能会 derail 预期的增长。这使得 Vanda Pharmaceuticals 的任何转机都远非保证。</p>
</div><p>Find out about the key risks to this Vanda Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 Vanda Pharmaceuticals 叙述的关键风险。</p>
</div><h2>Build Your Own Vanda Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>自建 Vanda Pharmaceuticals 叙述</h2>
</div><p>If you see Vanda Pharmaceuticals differently or want to draw your own conclusions, you can explore the fundamentals and share your perspective in just a few minutes, so go ahead and Do it your way</p>
<div class="lb-trans"><p>如果你对 Vanda Pharmaceuticals 有不同的看法或想得出自己的结论，可以在几分钟内探索基本面并分享你的观点，所以请随意按照自己的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Vanda Pharmaceuticals.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Vanda Pharmaceuticals 的 2 个关键回报的乐观情绪。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Level up your portfolio now by tapping into unique themes and growth potential that others might miss. Check out these handpicked opportunities and secure your next advantage before the crowd catches on:</p>
<div class="lb-trans"><p>通过挖掘独特的主题和其他人可能忽视的增长潜力，提升你的投资组合。查看这些精心挑选的机会，并在大众发现之前确保你的下一个优势：</p>
</div><ul>
<li>Unlock the potential of tomorrow’s high-yield investments by assessing income-focused opportunities across these 22 dividend stocks with yields &gt; 3% with yields surpassing 3%.</li>
<li>Spot powerful shifts in artificial intelligence by evaluating these 26 AI penny stocks with strong momentum and industry leadership in game-changing tech.</li>
<li>Ride the wave of innovation in decentralized finance by reviewing standouts among these 81 cryptocurrency and blockchain stocks transforming blockchain and digital payments.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过评估这些 22 只股息收益率超过 3% 的高收益投资，解锁明天的潜力。</li>
<li>通过评估这 26 只强劲势头和行业领导地位的 AI 便士股票，发现人工智能的强大变化。</li>
<li>通过审查这些 81 只正在改变区块链和数字支付的加密货币和区块链股票，乘风破浪于去中心化金融的创新。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

估值检查：在削减 2025 年收入指引并即将公布第三季度业绩后，Vanda 制药（VNDA）的表现如何